# Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Source: https://onco.cc/trials/nct03096093/  
OnCo record `nct03096093` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ACIT-1 in advanced solid tumours, run by Cancer Vaccines Limited, active and no longer recruiting.

## Summary

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer is a phase 1/2 interventional study registered as NCT03096093 by Cancer Vaccines Limited, with 34 participants enrolled, started 2017-04-25 and due to reach its primary completion in 2026-12. Interventions recorded: ACIT-1.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03096093
- Phase: 1/2
- Setting: A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients
- Sponsor: Cancer Vaccines Limited
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT03096093: https://clinicaltrials.gov/study/NCT03096093

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct03096093.json